TREATMENT WITH PAN DEACETYLASE (DAC) INHIBITOR PANOBINOSTAT (LBH589) DEPLETES EZH2 AND DNMT1, DEREPRESSES JUNB AND SENSITIZES ACUTE MYELOID LEUKEMIA CELLS TO DECITABINE

被引：0
|
作者：
Fiskus, W. [1 ]
Wang, Y. [1 ]
Rao, R. [1 ]
Atadja, P. [2 ]
Bhalla, K. N. [1 ]
机构：
[1] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA
[2] Novartis Inst Biomed Res Inc, Cambridge, MA USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0024
引用
收藏
页码：9 / 9
页数：1
相关论文
共 6 条
  • [1] Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
    Fiskus, Warren
    Buckley, Kate
    Rao, Rekha
    Mandawat, Aditya
    Yang, Yonghua
    Joshi, Rajeshree
    Wang, Yongchao
    Balusu, Ramesh
    Chen, Jianguang
    Koul, Sanjay
    Joshi, Atul
    Upadhyay, Sunil
    Atadja, Peter
    Bhalla, Kapil N.
    CANCER BIOLOGY & THERAPY, 2009, 8 (10) : 939 - 950
  • [2] Hydroxamate Pan-HDAC inhibitor LBH589 depletes EZH2 and DNMT1, partly through hsp90 inhibition and its chaperone association with DNMT1.
    Fiskus, Warren
    Herger, Bryan
    Rao, Rekha
    Atadja, Peter
    Bhalla, Kapil
    BLOOD, 2006, 108 (11) : 632A - 633A
  • [3] Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90
    Bhalla, K. N.
    Fiskus, W.
    Herger, B.
    Rao, R.
    Ustun, C.
    Jillella, A.
    Atadja, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Histone deacetylase inhibitors LBH589 and LAQ824 deplete Ezh2 and associated Polycomb Repressive Complex 2/3 proteins resulting in downregulation of HOXA9 and MEIS1 expression in human acute leukemia cells.
    Fiskus, W
    Pranpat, M
    Bali, P
    Kumaraswamy, S
    Boyapalle, S
    Rocha, K
    Balasis, M
    Atadja, P
    Bhalla, K
    BLOOD, 2005, 106 (11) : 697A - 697A
  • [5] Casein Kinase II Inhibitor Sensitizes the Anti-Tumor Effect of EZH2 Inhibitor By Suppressing FOSL1 Expression in Acute Myeloid Leukemia
    Yang, Chan
    Song, Chunhua
    Ge, Zheng
    BLOOD, 2023, 142
  • [6] AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML)
    Mims, Alice S.
    Walkers, Alison R.
    Hoellerbauer, Pia
    Huang, Xiaomeng
    Chan, Kenneth K.
    Klisovic, Rebecca B.
    Perrotti, Danilo
    Caligiuri, Michael A.
    Byrd, John C.
    Chen, Ching-Shih
    Blum, William
    Garzon, Ramiro
    Schwind, Sebastian
    Marcucci, Guido
    CANCER RESEARCH, 2012, 72
1